The federal Project Grant award in the amount of $999,940.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "DEVELOPMENT OF IMAGING OUTCOME MEASURES OF NEUROPROTECTION IN MULTIPLE SCLEROSIS USING ULTRA-HIGH GRADIENT DIFFUSION MRI". The award period is from June 1, 2024 to May 31, 2027. Through this grant, MGH...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
The Department of the Army Medical Command, through the Military Medical Research and Development (CFDA 12.420) federal grant program, awarded a $1,498,368 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a performance period from August 1, 2024 to July 31, 2027. The grant supports research to elucidate the molecular mechanisms of tumor-immune dynamics and evolution in response to radiation, in order to optimize treatment of high-...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), has been awarded a $1,000,236.00 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, effective April 1, 2024 through March 31, 2028, will fund research to "UNLOCK THE CTDNA MUTATIONAL PATTERNS FOR EARLY CANCER DETECTION AND NONINVASIVE BIOMARKERS." As a leading academic medical center and research...
The U.S. Defense Health Agency awarded a $1,626,932.00 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on March 1, 2025, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the grant will fund the "Detection and Quantification of Early Motor...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), received a $1,865,846 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on July 1, 2024. The funding will support the project "TARGETING NEUROIMMUNE AND EPITHELIAL SIGNALING FOR ECZEMA TREATMENT" through June 30, 2028. MGH, a leading academic medical center and research institution, will conduct biomedical research,...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,234,505.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award supports research to cotarget the tumor microenvironment and revolutionize antibody-drug conjugate...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,644,309 project grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct advanced biomedical research focused on "FUNCTIONAL MOLECULAR NETWORKS MODIFYING HIF2A ACTIVITY IN VHL TUMORS". The grant, awarded on February 1, 2025, will support MGH's innovative research efforts to transform healthcare for military service members,...
The federal Project Grant award of $999,806.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to study innate lymphoid cells as new targets to reduce vascularized composite tissue transplant rejection. The award, which runs from September 30, 2024 to September 29, 2027, will enable MGH to conduct innovative biomedical research,...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $771,627 project grant to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct advanced biomedical research on tuning and strike targeting of glioblastoma. The 24-month award period runs from August 1, 2025 to July 31, 2027. As a leading academic medical center and recipient of significant federal research funding, Massachusetts General Hospital will...